ERBB2 and breast cancer: These effects on cell proliferation and cell migration/invasion are possibly due to the decrease of HIF1α target mRNAs, such as SNAIL, VEGF and SLUG, (as shown in Figure S5) suggesting the use of As miR-429 as a new therapeutic option for HER2+ BC patients.